Novita Pharmaceuticals, Inc.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Holding
- Established
- 2010-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.novita-pharm.com
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Phase 1
Recruiting
- Conditions
- Advanced or Metastatic Solid Tumor Malignancies
- Interventions
- First Posted Date
- 2021-08-26
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Novita Pharmaceuticals, Inc.
- Target Recruit Count
- 140
- Registration Number
- NCT05023486
- Locations
- ๐บ๐ธ
Honor Health Research Institute, Scottsdale, Arizona, United States
๐บ๐ธUniversity of Arizona - Cancer Center, Tucson, Arizona, United States
๐บ๐ธUniversity of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1
Completed
- Conditions
- Breast CancerColon CancerOvary CancerAdvanced or Metastatic Treatment-refractory Solid Tumor MalignanciesLung CancerEsophagus CancerLiver CancerPancreas CancerProstate Cancer
- Interventions
- First Posted Date
- 2017-06-27
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Novita Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT03199586
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Hospital, New York, New York, United States
๐บ๐ธHonorHealth Research Institute, Scottsdale, Arizona, United States
๐บ๐ธCity of Hope National Medical Center, Duarte, California, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath